MedKoo Cat#: 406829 | Name: BI-9564
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BI-9564 is a potent and selective inhibitor of BRD9 and BRD7 bromodomains (Kds = 14.1 and 239 nM; IC50s = 75 nM and 3.4 µM, respectively). BI-9564 is useful in further exploring BRD9 bromodomain biology in both in vitro and in vivo settings. Selective inhibitors of bromodomain-containing protein 9 (BRD9) may have therapeutic potential in the treatment of human malignancies and inflammatory diseases.

Chemical Structure

BI-9564
BI-9564
CAS#1883429-22-8

Theoretical Analysis

MedKoo Cat#: 406829

Name: BI-9564

CAS#: 1883429-22-8

Chemical Formula: C20H23N3O3

Exact Mass: 353.1739

Molecular Weight: 353.42

Elemental Analysis: C, 67.97; H, 6.56; N, 11.89; O, 13.58

Price and Availability

Size Price Availability Quantity
50mg USD 750.00 2 Weeks
100mg USD 1,350.00 2 Weeks
200mg USD 2,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
BI-9564; BI 9564; BI9564.
IUPAC/Chemical Name
4-(4-((dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one
InChi Key
BJFSUDWKXGMUKA-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H23N3O3/c1-22(2)11-13-8-19(26-5)15(9-18(13)25-4)17-12-23(3)20(24)16-10-21-7-6-14(16)17/h6-10,12H,11H2,1-5H3
SMILES Code
O=C1N(C)C=C(C2=CC(OC)=C(CN(C)C)C=C2OC)C3=CC=NC=C13
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
BI-9564 is a BRD9/BRD7 bromodomains inhibitor with IC50s of 75 nM and 3.4 μM, respectively.
In vitro activity:
Target engagement in the cell was demonstrated in a semiquantitative FRAP assay using a green fluorescent protein–BRD9 fusion protein expressed in U2OS cells. BI-9564 showed inhibition of BRD9 in cells at 100 nM. The cellular response to BRD9 inhibition was assessed in a broad cancer cell line panel. Treatment of the panel with BI-9564 resulted in selective growth inhibition of a significant proportion of AML cell lines tested (Supporting Information Figure 31). Reference: J Med Chem. 2016 May 26;59(10):4462-75. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885110/
In vivo activity:
In order to evaluate the effect of BI-9564 in vivo, EOL-1 cells, stably transduced with a luciferase-expressing vector to allow continuous assessment of tumor load by bioluminescence, were injected in the tail vein of CIEA-NOG mice. Oral treatment with 180 mg/kg of BI-9564 was initiated on day 5 and applied daily (q.d.) with an interruption at days 18 and 19. A significant (p = 0.0086) reduction in tumor growth (measured in average radiance [p/s/cm2/sr]) compared to that of controls was observed on day 18, resulting in a median tumor growth inhibition (TGI) value of 52% (Figure 6a). Imaging data on day 18 provided evidence of a significantly reduced disease burden (Figure 6b) in mice treated with BI-9564. Reference: J Med Chem. 2016 May 26;59(10):4462-75. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885110/
Solvent mg/mL mM
Solubility
DMF 5.0 14.15
DMF:PBS (pH 7.2) (1:1) 0.5 1.41
DMSO 5.4 15.39
Ethanol 9.0 25.47
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 353.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Martin LJ, Koegl M, Bader G, Cockcroft XL, Fedorov O, Fiegen D, Gerstberger T, Hofmann MH, Hohmann AF, Kessler D, Knapp S, Knesl P, Kornigg S, Müller S, Nar H, Rogers C, Rumpel K, Schaaf O, Steurer S, Tallant C, Vakoc CR, Zeeb M, Zoephel A, Pearson M, Boehmelt G, McConnell D. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016 May 26;59(10):4462-75. doi: 10.1021/acs.jmedchem.5b01865. Epub 2016 Mar 10. PMID: 26914985; PMCID: PMC4885110.
In vitro protocol:
1. Martin LJ, Koegl M, Bader G, Cockcroft XL, Fedorov O, Fiegen D, Gerstberger T, Hofmann MH, Hohmann AF, Kessler D, Knapp S, Knesl P, Kornigg S, Müller S, Nar H, Rogers C, Rumpel K, Schaaf O, Steurer S, Tallant C, Vakoc CR, Zeeb M, Zoephel A, Pearson M, Boehmelt G, McConnell D. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016 May 26;59(10):4462-75. doi: 10.1021/acs.jmedchem.5b01865. Epub 2016 Mar 10. PMID: 26914985; PMCID: PMC4885110.
In vivo protocol:
1. Martin LJ, Koegl M, Bader G, Cockcroft XL, Fedorov O, Fiegen D, Gerstberger T, Hofmann MH, Hohmann AF, Kessler D, Knapp S, Knesl P, Kornigg S, Müller S, Nar H, Rogers C, Rumpel K, Schaaf O, Steurer S, Tallant C, Vakoc CR, Zeeb M, Zoephel A, Pearson M, Boehmelt G, McConnell D. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016 May 26;59(10):4462-75. doi: 10.1021/acs.jmedchem.5b01865. Epub 2016 Mar 10. PMID: 26914985; PMCID: PMC4885110.
1: Karim RM, Schönbrunn E. An Advanced Tool To Interrogate BRD9. J Med Chem. 2016 May 26;59(10):4459-61. doi: 10.1021/acs.jmedchem.6b00550. Epub 2016 Apr 27. PubMed PMID: 27120693. 2: Martin LJ, Koegl M, Bader G, Cockcroft XL, Fedorov O, Fiegen D, Gerstberger T, Hofmann MH, Hohmann AF, Kessler D, Knapp S, Knesl P, Kornigg S, Müller S, Nar H, Rogers C, Rumpel K, Schaaf O, Steurer S, Tallant C, Vakoc CR, Zeeb M, Zoephel A, Pearson M, Boehmelt G, McConnell D. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016 May 26;59(10):4462-75. doi: 10.1021/acs.jmedchem.5b01865. Epub 2016 Mar 10. PubMed PMID: 26914985; PubMed Central PMCID: PMC4885110.